Bone biologics effects 1-for-30 reverse stock split

Burlington, mass.--(business wire)--bone biologics corporation (nasdaq: bblg), a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effective on june 5, 2023 and that its common stock and warrants will begin trading on a split-adjusted basis with the open of the market on june 7, 2023. bone biologics' common stock and warrants will continue to trade on nasdaq under the symbols "bblg" and “bblgw”, respectively as a result of the rev.
BBLG Ratings Summary
BBLG Quant Ranking